- November 17, 2022– Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening – – Virtual Multiple Sclerosis…
- November 10, 2022NEW YORK, November 10, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…
- November 3, 2022– $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised…
- October 27, 2022– Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK, October 27, 2022 – Immunic,…
- October 20, 2022– Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo – – No New…
- October 10, 2022NEW YORK, October 10, 2022 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a clinical-stage biopharmaceutical company developing a…
- October 4, 2022NEW YORK, October 4, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…
- September 20, 2022– Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU‑856 in Single and 14-Day Multiple Dosing –…
- September 1, 2022NEW YORK, September 1, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- August 16, 2022NEW YORK, August 16, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…